Congress removes tax penalty for sick people joining drug trials
H.R. 4184 — To amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes. · Filed by Mike Kelly (R-PA) · 1 cosponsor · Introduced Jun 26, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill excludes compensation paid to people who participate in clinical trials from their taxable income and shields that income from counting against eligibility for federal assistance programs like Medicaid, SNAP, or housing aid. It applies to both direct payments for participation and reimbursement of trial-related expenses, effective for payments after December 31, 2025.
Why we flagged it
The bill's core function is straightforward: it creates a tax exclusion for clinical trial compensation and shields that income from means-testing for federal benefits. This is a targeted tax relief measure aimed at removing barriers to trial participation.
What the text implies
- Pharmaceutical and biotech companies may see increased trial enrollment, particularly among low-income and uninsured populations who previously avoided trials due to benefit loss—a material benefit to trial recruitment without explicit subsidy.
- The provision may disproportionately benefit large-scale, well-funded trials (typically run by major pharma) over small academic or rare-disease trials with smaller participant pools and lower compensation.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies (trial recruitment cost reduction); biotech firms (improved trial enrollment); contract research organizations (CROs)